Elamipretide cost explained: why Forzinity has no retail price yet, what research-grade vials run, and how insurance or clinical trials may cover it.
There is no published retail price for elamipretide in the United States because the drug has not been approved by the FDA for general sale. When people search for an elamipretide price today, they usually land on research-grade peptide vials sold strictly for laboratory work, and those commonly list between $100 and $400 each depending on size and purity. If a brand version — proposed under the name Forzinity — reaches the market, it would most likely carry a specialty-drug price measured in thousands of dollars per month before insurance.
Why Elamipretide Doesn't Have a Standard Price Yet
Elamipretide is an investigational mitochondria-targeted peptide developed by Stealth BioTherapeutics. Researchers have studied it in Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration, and heart failure. As of the latest public updates from its developer, elamipretide remains investigational in the US and has not been cleared for routine prescribing.
Because there is no approved product, elamipretide does not appear in the pharmacy pricing databases that power most drug-cost tools. Patients who have accessed it generally did so through one of three routes:
- An elamipretide clinical trial, where the sponsor supplies the drug at no charge to participants.
- Expanded access, also called compassionate use, which requires FDA authorization and cooperation from the manufacturer.
- Research-grade material bought online for laboratory work, which is legal to sell but not approved for human use.
The third route is where almost all of the visible pricing comes from, and it is also the route with the least oversight. That single fact explains why online prices for the same compound vary so widely.
What Elamipretide Costs Right Now
Real out-of-pocket cost depends entirely on how someone gets the peptide. The table below summarizes the realistic US range today.
| Access route | Typical out-of-pocket cost | What the number includes |
|---|---|---|
| Clinical trial | $0 for the drug | Sponsor covers the drug; travel, time, and clinic visits are on the participant |
| Expanded access (compassionate use) | Often $0, sometimes a few hundred dollars | Manufacturers frequently donate the drug; provider and infusion fees may bill separately |
| Research-grade vial (lab use only) | About $100 to $400 per vial | Vial size, purity, and supplier reputation drive the spread |
| Gray-market peptide clinic injectables | Highly variable | Unverified sourcing with no legal prescription pathway for an unapproved drug |
| Future approved brand (Forzinity, if approved) | Not established | No list price has been published |
What Forzinity Could Cost If It Reaches the Market
No list price exists for a brand elamipretide product, so any forecast is an estimate. Manufacturers set the launch price, then insurers, pharmacy benefit managers, and Medicare negotiate from there.
For context, vyleesi cost usually lands in the high three figures per month, and lipo c injection cost is typically far lower because the product is compounded rather than approved. If you have ever looked up how much does aod 9604 cost, you have seen the same pattern: research-grade vials stay cheap, approved drugs do not.
| Product | US status | Commonly reported price range |
|---|---|---|
| Vyleesi (bremelanotide) | FDA-approved | Roughly $800 to $1,200 per month before insurance |
| Lipo-C injection | Compounded, not an approved drug | About $25 to $75 per injection at clinics |
| AOD-9604 | Not approved; research-grade only | About $50 to $150 per vial |
| Elamipretide (research grade) | Investigational | About $100 to $400 per vial |
| Forzinity (brand elamipretide) | Not available as a standard prescription | No published list price |
Ultra-rare disease therapies frequently launch above $100,000 per year in the United States, and Barth syndrome affects only a few hundred people worldwide. A tiny patient population combined with orphan-drug status is the strongest argument that a future Forzinity price would be high rather than low.
Elamipretide Uses, Structure, and What the Molecule Is
Interest in elamipretide uses comes from its mechanism. The peptide is designed to concentrate in the inner mitochondrial membrane and reduce oxidative stress, which makes it a candidate for conditions where cellular energy production fails.
Chemically, elamipretide is a short tetrapeptide built from four amino acids, including a dimethyltyrosine residue and D-form amino acids that help it penetrate cells. Four amino acids are cheap to assemble compared with a full protein, but those unusual building blocks and the purification steps add manufacturing cost.
The name is generally pronounced el-uh-MIP-ri-tide. Pronunciation does not change the price, but it does help when you are searching clinical registries or calling a specialty pharmacy.
What Drives the Price Per Vial
Research-grade pricing is not random. A handful of factors explain most of the difference between a $90 vial and a $400 vial.
- Purity and testing: Material verified at 98% or higher by HPLC, with a third-party certificate of analysis, costs more than untested powder.
- Vial size: A 50 mg vial is not priced at five times a 10 mg vial, but it usually costs noticeably more.
- Cold-chain shipping: Insulated packaging and overnight delivery add real money to every order.
- Supplier transparency: Vendors that publish batch-specific test results charge for that documentation.
- Order volume: Bulk purchases lower the per-vial price, which is why group buys appear in research forums.
One factor that does not drive the price is FDA approval, because no approval exists. Elamipretide is not FDA-approved for human use in the United States, so no research-grade vial should be marketed as a medicine.
Insurance, Trials, and Safety Basics
No US insurer covers elamipretide today, because there is no approved product and therefore no billing code. If approval happens, coverage would likely require prior authorization, a documented diagnosis, and step therapy through other treatments. Manufacturer patient-assistance programs and rare-disease foundations commonly step in once a drug is on the market.
Clinical trials and expanded access programs remain the only supervised ways to receive elamipretide. Trial sponsors cover the drug itself, and expanded access requests require both FDA permission and the manufacturer's agreement to supply material.
Research-grade peptides are not produced under sterile pharmaceutical conditions, are not potency-verified for human dosing, and carry no guarantee of identity or purity. Anyone weighing elamipretide for a diagnosed mitochondrial condition should speak with a healthcare professional and pursue a supervised trial rather than an online vial. Nothing on this page is medical advice.
Frequently Asked Questions
How much does elamipretide cost?
There is no official retail price because elamipretide is not FDA-approved for human use in the United States. Research-grade vials sold for laboratory work typically list between $100 and $400 each, depending on vial size and purity. Clinical trial participants receive the drug at no cost from the study sponsor, and a future approved brand product would likely carry a specialty-drug price.
Is Forzinity available in the United States?
Forzinity is the proposed brand name for elamipretide, and it is not available as a standard prescription in the US. Access currently happens through clinical trials or expanded access programs, both of which require FDA and manufacturer involvement. Patients should ask a specialist about eligibility instead of buying research-grade peptide online.
Will insurance cover elamipretide?
No US insurer covers elamipretide today because no approved product exists and no billing code has been issued. If the FDA approves it, coverage would depend on the labeled indication, prior authorization rules, and each plan's formulary. Manufacturer assistance programs and rare-disease foundations often help with copays after a drug reaches the market.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.